Innovations in Oncology Diagnostics
Emerging Trends & Opportunities for ctDNA MRD in Clinical Trials
Tuesday February 8, 2022 | 8.00am PT | 11.00am ET
This Innovations in Oncology Diagnostics Engager is an exclusive event created to provide Directors, VPs, and Functional Executives within pharma the opportunity to discuss and evaluate the clinical trial use cases for ctDNA molecular residual disease (MRD) and learn how they can unlock a new clinical trial paradigm.
This unique forum can help you understand how ctDNA detection and monitoring improves targeted enrollment of high-risk patient populations to increase drug efficacy, provides early signals of response to treatment, and enables earlier planning for next-phase clinical trials. Learn how leading biopharma organizations are using ctDNA MRD, how investors view ctDNA in supporting early efficacy readouts, and how you may benefit from using ctDNA MRD in clinical trials to accelerate clinical development.
Join us for an insightful panel discussion among pharma and research key opinion leaders!
ABOUT OUR HOST
Natera has developed Signatera, a tumor-informed circulating tumor DNA (ctDNA) test, capable of detecting the presence of molecular residual disease (MRD) down to a single tumor molecule in a tube of blood.
With 20+ peer-reviewed publications and 60+ presentations, Signatera has been clinically validated in multiple cancer types including colorectal, non-small cell lung, breast, and bladder cancers. Signatera is being used in multiple prospective studies, received CMS Local Coverage Determination for immunotherapy monitoring and Stage II-IV colorectal cancer, and is available to biopharmaceutical customers and clinicians globally
Look deeper at: